Every earnings call for JAGSNPHARM — management tone, guidance, KPIs and promise tracking, quarter by quarter.
JAGSNPHARM · 5 transcripts · Healthcare · latest Q4 FY26Jagsonpal Pharmaceuticals Limited has 5 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Revenue (Q4 FY26) ₹64 cr (+10% YoY); EBITDA (Q4 FY26) ₹11 cr (+9% YoY); EBITDA Margin (Q4 FY26) 16%. Q4 FY26 Revenue grew 10% YoY to INR64 crores, driven by sharpened execution focus.
Read full transcript & analysisRevenue (Q3 FY26) ₹73 cr; EBITDA (Q3 FY26) ₹17 cr; EBITDA Margin (Q3 FY26) 22.7%. PAT grew by 10% YoY to INR 12.5 crores in Q3 FY26.
Read full transcript & analysisRevenue (Q3) ₹73 cr; EBITDA (Q3) ₹17 cr; EBITDA Margin (Q3) 22.7%. Nine-month revenue grew 6% YoY to INR 223 crores.
Read full transcript & analysisRevenue ₹76 cr (+23% YoY); EBITDA Margin 20.8%; PAT 108 million (+560% YoY). Revenue grew 23% YoY to ₹75.5 crores.
Read full transcript & analysisRevenue ₹76 cr (+23% YoY); Operating EBITDA (pre-ESOP) ₹16 cr (+24% YoY); Operating EBITDA Margin 20.8%. Revenue grew 23% YoY to ₹75.5 crores.
Read full transcript & analysis